Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
- MHLW Orders Revision of Package Inserts for Plavix
April 24, 2015
- Polyethylene Glycol Has Great Unmet Medical Need: Panel
April 23, 2015
- MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
- Find Solid Candidates from Early Development Stage: MHLW’s Mori
April 23, 2015
- Ease Post-Marketing Burdens for Intractable Disease Treatments: JPMA Exec
April 22, 2015
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 6 - 19
April 20, 2015
- Govt Checks on Progress of Healthcare R&D Promotion Plan
April 20, 2015
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- Who Will Foot the Bill for Cost-Effective Assessments?: Chuikyo Chair
April 16, 2015
- Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
- PAFSC 1st Committee to Discuss Add’l Indication for Cymbalta on April 28
April 15, 2015
- “Proper Management” Essential in Company Funding of Academic Research: MHLW Official
April 15, 2015
- PMDA Invites People with Broad Perspective from the Medical Community to Join PMDA: Chief Executive
April 15, 2015
- MHLW Official Introduces Patient ADR Reporting System
April 15, 2015
- Cost-Effectiveness Case Study to Be Reported to Chuikyo in May: Official
April 14, 2015
- If Cost-Effective Assessment Is Used to Set Drug Prices, Focus Will Be on Impact on Pricing Rules: Ex-Chuikyo Member
April 14, 2015
- Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…